menu

Menu

Home Aims and Scope statement Editorial board Instructions for authors Statement of Informed consent Statement of Human and Animal Rights Editorial process and peer review Copyright and License - Index and Abstract service - Open Access How to submit your article Contacts Archive

Latest Articles

PAG. 2193.
Medica 3 / 2022

MANAGEMENT OF PATIENTS WITH ALLERGIC RHINITIS IN THE PRIMARY CARE SETTING: A CROSS-SECTIONAL MULTICENTER STUDY IN DAILY PRACTICE (THE MAPRAP STUDY)

PAG. 1725.
Medica 3 / 2022

COVID-19 AS A HEALTH EDUCATION CHALLENGE: A PERSPECTIVE CROSS-SECTIONAL STUDY

PAG. 1719.
Medica 3 / 2022

Effect of lamivudine combined with thymosin on postoperative recurrence of alcoholic hepatitis complicated with liver cancer

You are here: Archive 2021 Medica 6 Pag 3375

CLINICAL EFFICACY OF RADIOFREQUENCY ABLATION FOR PRIMARY LIVER CANCER AND ITS EFFECTS ON T LYMPHOCYTE SUBSETS, SIL-2R, TSGF LEVELS AND PROGNOSIS

  Pdf

Authors

Weidi Ming1, Jin Liu2, Xiaochun Chen2, Jialin Liu3, Lei Sun1, Zhengming Wang1*


Departments

1Department of radiotherapy, General Hospital of PLA Rocket Force, Beijing 100088, China - 2Department of radiology. Beijing Jingmei Group General Hospital, Beijing 102399, China - 3Department of radiology.Beijing Friendship Hospital Pinggu Campus, Beijing 101299, China

Abstract

Objective: To determine the clinical efficacy of radiofrequency ablation (RFA) for primary hepatocellular carcinoma and analyze the effects of RFA treatment on T lymphocyte subsets, soluble interleukin-2 receptor (sIL-2R), tumor specific growth factor (TSGF) levels, and prognosis. 

Methods: A total of 48 patients with liver cancer admitted to the cardiovascular department of our hospital from May 2017 to April 2018 were randomized into observation and control groups of 24 patients each. The control group received conventional embolization chemotherapy intervention, and the observation group received RFA in conjunction with conventional embolization chemotherapy. After treatment, the clinical outcomes and complications of the two groups were observed. The changes in T lymphocyte subsets [CD3+, CD4+, CD8+ and CD4+/CD8+], sIL-2R, and TSGF in the two groups were compared. 

Results: The total effective rate of treatment in the observation group was 87.50%, significantly higher than that of the control group, 70.83%, (P<.05); The total incidence of complications in the observation group was 29.17%, significantly lower than that in the control group, 58.33% (P<.05). After treatment, the levels of CD3+, CD4+, and CD4+/CD8+ T cells in the observation group were significantly increased compared with the control group, and the levels of CD8+ cells were significantly decreased from before-treatment levels (P<.05). After treatment, the sIL-2R and TSFG levels in the observation group were significantly lower than those in the control group (P<.05). 

Conclusion: Radiofrequency ablation has a significant clinical effect in the treatment of primary liver cancer that can significantly improve outcomes, effectively regulate the balance of T lymphocyte subsets, reduce sIL-2R and TSGF, and improve the quality of life of patients.


Keywords

Clinical efficacy, primary liver cancer, prognosis, radiofrequency ablation, RFA, sIL-2R, T lymphocyte subsets, TSGF.

DOI:

10.19193/0393-6384_2021_6_531

Back